Talshir Medical Technologies Ltd.

Talshir Medical Technologies Ltd., operating as RevitalVision, develops FDA-cleared perceptual learning and vision training software designed to improve the brain's visual processing. RevitalVision is indicated for amblyopia (lazy eye) in patients aged 9 and older, making it the only FDA-cleared product with efficacy claims for adult amblyopia as a standalone therapy without upper age limits. The platform uses proprietary perceptual learning technology supported by randomized controlled, double-blind clinical studies published in peer-reviewed journals. Beyond amblyopia treatment, RevitalVision addresses post-cataract surgery vision recovery, low myopia, presbyopia (read without glasses), sports vision enhancement, post-LASIK vision improvement, and low vision from eye diseases. Clinical evidence demonstrates an average 2.5-line improvement on ETDRS visual acuity charts, 100% improvement in contrast sensitivity (FACT sine wave), and enhanced stereo and binocular functions. The company operates a B2B2C model where ophthalmologists, optometrists, orthoptists, and optometry doctors subscribe to monthly or annual plans, then offer therapy programs to patients. Training sessions are administered at-home (3–4 per week) with periodic in-clinic assessments. The American Medical Association has assigned two unique CPT codes (0687T and 0688T) for RevitalVision amblyopia therapy, effective January 2022, supporting insurance coverage pathways. More than 30 clinical studies across the USA, Europe, and Asia support efficacy, with 12 published in peer-reviewed journals. The company operates globally with approximately 400 clinics and 15,000 treated patients reported.